Brainstorm Cell Therapeutics, Inc. (BCLI)
1.123
-0.04
(-3.40%)
USD |
OTCM |
Aug 28, 16:00
Brainstorm Cell Therapeutics Cash from Operations (Quarterly) : -0.895M for June 30, 2026
Cash from Operations (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.895M |
| March 31, 2026 | -1.32M |
| December 31, 2025 | -0.74M |
| September 30, 2025 | -1.102M |
| June 30, 2025 | -3.502M |
| March 31, 2025 | -1.631M |
| December 31, 2024 | -1.048M |
| September 30, 2024 | -3.299M |
| June 30, 2024 | -1.683M |
| March 31, 2024 | -3.063M |
| December 31, 2023 | -3.285M |
| September 30, 2023 | -6.409M |
| June 30, 2023 | -6.778M |
| March 31, 2023 | -3.986M |
| December 31, 2022 | -4.648M |
| September 30, 2022 | -4.85M |
| June 30, 2022 | -6.134M |
| March 31, 2022 | -3.688M |
| December 31, 2021 | -5.508M |
| September 30, 2021 | -6.46M |
| June 30, 2021 | -5.329M |
| March 31, 2021 | -8.968M |
| December 31, 2020 | -7.578M |
| September 30, 2020 | -6.924M |
| June 30, 2020 | -5.662M |
| Date | Value |
|---|---|
| March 31, 2020 | -15.03M |
| December 31, 2019 | -3.278M |
| September 30, 2019 | -3.626M |
| June 30, 2019 | -3.508M |
| March 31, 2019 | -0.835M |
| December 31, 2018 | -3.723M |
| September 30, 2018 | -6.594M |
| June 30, 2018 | 0.055M |
| March 31, 2018 | -2.126M |
| December 31, 2017 | -2.935M |
| September 30, 2017 | 3.843M |
| June 30, 2017 | -1.63M |
| March 31, 2017 | -1.642M |
| December 31, 2016 | -1.196M |
| September 30, 2016 | -0.275M |
| June 30, 2016 | -1.406M |
| March 31, 2016 | -2.981M |
| December 31, 2015 | -1.291M |
| September 30, 2015 | -2.53M |
| June 30, 2015 | -1.65M |
| March 31, 2015 | -1.937M |
| December 31, 2014 | -2.007M |
| September 30, 2014 | -1.119M |
| June 30, 2014 | -0.97M |
| March 31, 2014 | -0.391M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| NovelStem International Corp. | -0.0336M |
| Summit Therapeutics, Inc. | -140.55M |
| Kezar Life Sciences, Inc. | -7.445M |
| Protara Therapeutics, Inc. | -15.39M |
| Clene, Inc. | -2.578M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Financing (Quarterly) | 0.898M |
| Free Cash Flow | -4.057M |
| Free Cash Flow Per Share (Quarterly) | -0.0811 |
| Free Cash Flow to Equity (Quarterly) | -0.781M |
| Free Cash Flow to Firm (Quarterly) | -0.653M |
| Free Cash Flow Yield | -32.75% |